

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057

CIN: L24110MH1981PLC025884



## AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2015

### PART I

Rupees in lakhs

		Quarter ended			Half Year ended		Year ended
		30.09.2015 (Audited)	30.06.2015 (Unaudited)	30.09.2014 (Audited)	30.09.2015 (Audited)	30.09.2014 (Audited)	31.03.2015 (Audited)
1	a. Net Sales / Income from Operations	2,276.22	2,411.16	2,233.49	4,685.60	4,232.14	8,634.22
	b. Other Operating Income	20.89	53.84	81.10	74.74	152.83	198.57
	<b>Total Income</b>	<b>2,297.11</b>	<b>2,465.00</b>	<b>2,314.59</b>	<b>4,760.34</b>	<b>4,384.97</b>	<b>8,832.79</b>
2	Total Expenditure :						
	a. Consumption of Raw Material	1,060.07	1,075.48	1,224.58	2,125.95	2,024.99	4,398.70
	b. (Increase)/Decrease in stock in trade and work in progress	(110.90)	25.26	(113.18)	(85.20)	47.48	(234.73)
	c. Employees Cost	315.95	278.76	259.55	594.71	447.55	940.24
	d. Depreciation	65.25	64.02	43.54	129.27	132.75	259.68
	e. Other Expenditure	530.91	557.42	529.98	1,098.10	1,063.38	2,262.28
	<b>g. Total</b>	<b>1,861.28</b>	<b>2,000.94</b>	<b>1,944.47</b>	<b>3,862.83</b>	<b>3,716.15</b>	<b>7,626.17</b>
3	Profit from operations before other income, finance costs (1 - 2)	435.83	464.06	370.12	897.51	668.82	1,206.62
4	Other Income	4.28	2.52	2.58	6.80	4.34	13.14
5	Profit from ordinary activities before finance costs (3 + 4)	440.11	466.58	372.70	904.31	673.16	1,219.76
6	Finance Costs	(28.31)	(30.67)	(38.54)	(60.06)	(73.77)	(125.47)
7	Profit from ordinary activities before tax (5 - 6)	411.80	435.91	334.16	844.25	599.39	1,094.29
8	Exceptional Items	-	-	(0.16)	-	(0.16)	191.62
9	<b>Net Profit for the Period (7 - 8)</b>	<b>411.80</b>	<b>435.91</b>	<b>334.00</b>	<b>844.25</b>	<b>599.23</b>	<b>1,285.91</b>
10	Tax Expense	(156.32)	(158.39)	(105.57)	(314.72)	(196.64)	(452.90)
11	Net Profit (9 - 10)	255.48	277.52	228.43	529.53	402.59	833.01
12	Extra ordinary item ( net of tax expenses )	-	-	-	-	-	-
13	Net Profit/Loss for the period (11-12)	255.48	277.52	228.43	529.53	402.59	833.01
14	Share of Profit / Loss of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit/loss of associates (13-14-15)	255.48	277.52	228.43	529.53	402.59	833.01
17	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A.	N.A.	N.A.	N.A.
19	Earnings Per Share (EPS)						
	a) Basic	4.14	4.49	3.70	8.57	6.52	13.48
	b) Diluted	4.14	4.49	3.70	8.57	6.52	13.48
<b>PART II</b>							
<b>A</b>	<b>Particulars of Shareholding</b>						
1	Public Shareholding						
	- Number of Shares	2,094,802	2,189,837	2,294,823	2,094,802	2,294,823	2,294,723
	- Percentage of Shareholding	33.91%	35.45%	37.14%	33.91%	37.14%	37.14%
2	Promoters and promoter group shareholding						
	a) Pledged / Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares ( as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered						
	- Number of Shares	4,083,222	3,988,187	3,883,201	4,083,222	3,883,201	3,883,301
	- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares ( as a % of the total share capital of the company)	66.09%	64.55%	62.86%	66.09%	62.86%	62.86%
	<b>Particulars</b>	3 months Ended 30th September 2015					
<b>B</b>	<b>Investors Complaints</b>						
	Pending at the beginning of the quarter	-					
	Received during the quarter	1					
	Disposed off during the quarter	1					
	Remaining unresolved at the end of the quarter	-					

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057

CIN: L24110MH1981PLC025884



(Rupees in lakhs)

Particulars	As at 31st September 2015 (Audited)		As at 31 March 2015 (Audited)	
<b>A EQUITY AND LIABILITIES</b>				
<b>1 Shareholders' funds</b>				
(a) Share capital	308.90		308.90	
(b) Reserves and surplus	3,502.26		2,972.73	
		3,811.16		3,281.63
<b>2 Non-current liabilities</b>				
(a) Long-term borrowings	102.14		157.04	
(b) Deferred tax liabilities (net)	113.81		117.09	
		215.95		274.13
<b>3 Current liabilities</b>				
(a) Short-term borrowings	1,222.11		959.13	
(b) Trade payables	1,307.38		1,713.17	
(c) Other current liabilities	253.76		214.42	
(d) Short-term provisions	303.75		209.24	
		3,087.00		3,095.96
<b>TOTAL</b>		<b>7,114.11</b>		<b>6,651.72</b>
<b>B ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Fixed assets				
(i) Tangible assets	1,699.33		1,714.50	
(ii) Intangible assets	24.53		28.49	
(iii) Capital work-in-progress	316.12		109.58	
(b) Long-term loans and advances	532.24		396.38	
		2,572.22		2,248.95
<b>2 Current assets</b>				
(a) Current investments	254.39	-	207.39	-
(b) Inventories	1,276.26		1,212.07	
(c) Trade receivables	2,553.01		2,596.64	
(d) Cash and cash equivalents	251.11		186.33	
(e) Short-term loans and advances	199.37		197.68	
(f) Other current assets	7.75		2.66	
		4,541.89		4,402.77
<b>TOTAL</b>		<b>7,114.11</b>		<b>6,651.72</b>

1. The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on October 30, 2015
2. The Company's operations consist only of one segment i.e. pharmaceuticals, hence Segment Reporting required under AS17 is not applicable.
3. The figures of the corresponding period have been regrouped wherever necessary.

For and On behalf of Board of Directors,

Mumbai  
30 October 2015

Rahul Nachane  
**Managing Director**